CLSI Publishes Newborn Screening Document NBS08—Newborn Screening for Hemoglobinopathies, 1st Edition
11/5/2019
Wayne, Pennsylvania, USA—The Clinical and Laboratory Standards Institute (CLSI) has published NBS08—Newborn Screening for Hemoglobinopathies, 1st Edition. NBS08 describes the newborn screening (NBS) processes for testing dried blood spot specimens to detect hemoglobinopathies and thalassemias not usually evident at birth. Hemoglobinopathies and thalassemias are clinically significant congenital red blood cell disorders caused by structural or other hemoglobin abnormalities, resulting in various clinical manifestations. Early detection is critical, because without treatment, these conditions lead to increased morbidity and mortality. This guideline discusses various NBS approaches, including:
- Equipment considerations.
- Laboratory screening methodologies.
- Short-term and long-term follow-up processes.
- Future screening possibilities.
For more information about NBS08, contact Patrick McGinn at pmcginn@clsi.org or +1.484.588.5933.
CLSI sets the standard for quality in medical laboratory testing. A not-for-profit membership organization, CLSI brings together the global laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine.
For over 50 years, our members, volunteers, and customers have made CLSI a respected, transformative leader in the development and implementation of medical laboratory testing standards. Through our unified efforts, we will continue to set and uphold the standards that drive quality test results, enhance patient care delivery, and improve health care around the world.
By using CLSI standards, laboratorians can improve process quality, speed the development of standard operating procedures, and implement safer practices with greater ease and efficiency.